bluebird bio (BLUE)

BLUE was delisted on the 30th of May, 2025.

• Market cap: $48.7M
• Sector: Healthcare
• Industry: Biotechnology

About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.

Employees: 375